Share Price
~$30
snapshot March 2026
Market Cap
~$34B
NASDAQ | USD
Revenue 2025
$17.3B
+4.3% Y/Y | 5-year high
Net Income 2025
$1.41B
2024: ($1.64B) | EPS $1.23
Gross Margin 2025
51.8%
2022: 46.7% | consistent improvement
Net Debt
$13.3B
2024: $14.5B (-$1.2B)
1 Company Profile
Teva Pharmaceutical Industries is the world’s largest generic-drugs company, founded in 1901 in Jerusalem and today operating in more than 60 countries with headquarters in Tel Aviv. The company is dual-listed — traded on NASDAQ (TEVA) and on the Tel Aviv Stock Exchange, and is a constituent of the TA-35 index. Teva is regarded as one of the flagship stocks of the Israeli pharmaceutical sector, and although it is a global company with most of its activity in the US and Europe, it serves as a marker and benchmark for the Israeli biotech and pharma economy. The company combines a massive generic business — hundreds of products across 60+ countries — with a branded specialty portfolio led by Austedo and Ajovy, and a long-running turnaround strategy following the Copaxone patent cliff.
| Product | Indication | Strategic Role |
|---|
| AUSTEDO | Tardive Dyskinesia + Huntington | Core growth engine — blockbuster potential |
| AJOVY | Migraine (CGRP) | Global competition vs. Aimovig, Emgality |
| UZEDY | Schizophrenia (LAI) | New product — long-acting injectable |
| COPAXONE | Multiple Sclerosis | Legacy product in decline |
| Generic Portfolio | Hundreds of products | Broad base — Scale advantage |
Source: SEC 10-K FY2025
2 Key Financial Observations
This summary is not a recommendation. It is a factual list of key financial metrics.
Performance — 5 Years ($M)
| Year | Revenue | Net Income | Gross Margin |
|---|
| 2021 | 15,878 | 417 | 47.8% |
| 2022 | 14,925 | (2,446) | 46.7% |
| 2023 | 15,846 | (559) | 48.2% |
| 2024 | 16,544 | (1,639) | 48.7% |
| 2025 | 17,258 | 1,410 | 51.8% |
Cash Flow & Debt ($M)
| Metric | 2024 | 2025 |
|---|
| Operating Cash Flow | 1,247 | 1,649 |
| FCF | 749 | 1,148 |
| Interest Paid | 1,004 | 950 |
| Total Debt | 17,783 | 16,806 |
| Net Debt | 14,483 | 13,250 |
| Equity | 5,373 | 7,910 |
Missing data: Pipeline R&D detail, detailed annual maturity schedule, geographic breakdown of future settlements.
GAAP Net Income — 5 Years ($M)
FCF vs. Interest Paid ($M)
Operating Cash Flow — Trend ($M)
3 Industry & Competitive Context
Global pharma — a non-cyclical market with stable demand across economic conditions. The generics market is competitive and fragmented; the innovative market is more concentrated. The US IRA regulation and Medicare pricing pressure represent a headwind; biologic patent expirations open a growing biosimilars market.
| Competitor | Primary Area | Structural Difference |
|---|
| Sandoz (Novartis spin-off) | Generics | Most direct competitor in generics |
| Viatris | Generics + Brands | Mylan-Upjohn merger |
| Sun Pharma | Indian generics | Lower manufacturing cost |
| AbbVie | Innovative — CNS | Competes with AUSTEDO |
| Neurocrine Biosciences | INGREZZA | Direct competitor to AUSTEDO |
4 Risk Factors
| Risk | Context |
|---|
| Debt Burden | $16.8B total debt, ~$950M annual interest. Every rate decline is a tailwind, and every widening of credit spreads makes refinancing more expensive |
| Goodwill $16B (39% of assets) | Teva has recorded heavy goodwill impairments in the past. Sensitive to recurring impairment if operations weaken |
| Product Concentration | A significant portion of growth depends on AUSTEDO. Generic competitor entry after patent expiry — material risk |
| Opioid Litigation | Teva paid ~$467M in 2025 and $761M in 2024 in settlements. Most settlements are closed, but new claims are possible |
| Generic Price Erosion | Persistent price pressure from Indian and Chinese competitors. Forces a shift toward innovation |
| US Regulation | IRA + Medicare price negotiation — impact revenue from leading drugs |
5 Analytical Lens — The Questions We Ask
In professional company analysis, the question is not "is this good?" but rather "through which lenses must this company be examined so that we do not miss what matters most?" At Bakshi Finance, every analysis passes through six lenses. The text below is not an evaluation — it is the mapping of the questions this analysis is meant to answer.
This framework is intended to structure analysis, not to produce an investment conclusion.
Growth
Revenue grows at 4-6% since 2023, primarily from AUSTEDO. How much is mix-shift (innovation replacing generics) versus volume growth? What is the outlook once AUSTEDO loses patent protection? Can the biosimilars pipeline replace that revenue?
Profitability
Gross margin improved from 46.7% to 51.8% over three years. How much is structural (mix) vs temporary (cost savings after restructuring)? What is the ratio between GAAP profit (volatile) and Non-GAAP (~22.9% operating)?
Leverage
$16.8B debt, $950M annual interest, Debt/EBITDA ~3.4×. What is the maturity schedule? What percentage is fixed vs variable? How will Fed cuts in 2026-2027 affect refinancing costs?
Competitive Position
The world’s largest generic portfolio (60+ countries) = scale advantage. Is scale a real moat in a market where Indians and Chinese manufacture at lower cost? Where does AUSTEDO stand against INGREZZA?
Management Quality
Richard Francis has led a dramatic turnaround since 2023. How personal-dependent is the turnaround on him? What is the strategy after debt reduction completes — dividend reinstatement? Acquisitions? R&D investment?
Business Complexity / Risk
Teva operates across four segments, dozens of countries, varied regulations. Where would a simplistic analysis go wrong? How should one treat the $1.8B GAAP vs Non-GAAP gap? What are the implications of an accumulated deficit of $13.8B for future dividends?
6 Scenario Framework
Scenarios are descriptive, not predictive. They outline possible conditions, not expected outcomes.
These scenarios carry no probability assessment, no preferred direction, and no expectation regarding which, if any, will materialise.
Constructive Scenario — if the following conditions hold:
The profitability inflection seen in 2025 continues — gross margins hold above 50%, AUSTEDO continues toward $1B+ in revenue, new biosimilars enter the market, and the Fed reduces rates enabling lower-cost debt refinancing. Under these conditions, net debt continues to decline at $1B+ per year, FCF improves, and dividend reinstatement becomes possible in 2027-2028.
Base Scenario — if current trends continue:
Revenue grows 3-5% annually, gross margins stable around 50%, net debt falls at ~$1B per year, rates remain stable. One-off expenses (settlements, restructuring) continue but diminish. Free cash flow stabilises at $1.0-1.3B annually.
Adverse Scenario — if the following risks materialise:
Additional goodwill impairment (>$1B) pressures equity, new opioid claims at meaningful scale, AUSTEDO encounters patent challenges or earlier competition than expected, or renewed rate increases raise refinancing costs. Under these conditions, FCF erodes and debt reduction slows.
Scenarios describe conditions, not forecasts. There is no preferred direction and no probability assessment expressed in this framework.
7 How to Think About This Company
Teva is not a typical pharmaceutical company — it is a turnaround story that is not yet complete. Since 2017, the company has been recovering from the failed Actavis acquisition (2016, $40B) which created a historic debt load. Over seven years the company reported losses, cumulative goodwill impairments exceeding $4B, and opioid settlements in the billions. 2025 was a genuine inflection — the first GAAP profit since 2021, gross margin at an all-time high of 51.8%, and net debt down $1.2B. The real question in analysing Teva is not "is the turnaround real" (it is), but rather "is it sustainable without the one-off sales and temporary cost tailwinds?"
The critical variables to monitor are three. First, the AUSTEDO trajectory — the product drives most of the medium-term growth story. The question is not just whether it continues growing, but how much of the growth is market expansion (new patients) versus market-share capture (from INGREZZA). Second, the debt-reduction path — net debt fell from $14.5B to $13.3B in 2025, which is excellent; but $13.3B is still an enormous burden. The question is pace — whether the company can reach below $10B by 2028. Third, the GAAP–Non-GAAP gap. The ~$1.8B gap in 2025 is a material decline from $2.5B+ in prior years, but it is still material. Closing that gap is a meaningful part of what will define 2026-2027 true earnings.
Where the analysis may go wrong. First error — treating GAAP profit of $1.41B as "normal". This is an inflection-year profit, helped by a positive working-capital swing, lower settlement expense, and one-time AUSTEDO revenue upside. The question is the reasonable run-rate for 2026-2027 — likely lower. Second error — assessing debt without assessing interest. $16.8B of gross debt is a scary number; but $950M of annual interest is what affects FCF day to day. The right measure for this company is Interest Coverage (4.2× Non-GAAP), not debt/EBITDA alone. Third error — treating $16B of goodwill as "an asset". In reality, it is a residual of the Actavis acquisition that has already been impaired by $4B+. Any stress on operations could trigger another impairment test.
What distinguishes professional analysis of Teva from headlines. Headlines on Teva speak of "turnaround" or of "heavy debt". Professional analysis addresses three things: (a) what distinguishes one-off expenses that should decline from recurring ones (opioid settlements ending, restructuring yes, but R&D continues); (b) FCF sensitivity to interest cost — every 1% decline in credit spread = $150M+ of additional FCF per year; (c) the post-AUSTEDO scenario. These are not what one buys or sells — they are what one asks before deciding.
The difference between surface-level analysis and professional thinking often lies in the variables that are not immediately visible.
The difference between surface-level analysis and professional thinking often lies in the variables that are not immediately visible.
8 Sources & Data
| # | Source | Date | Type |
|---|
| 1 | SEC EDGAR — Form 10-K FY2025 (P1720750-00) | March 2026 | Official — SEC |
| 2 | SEC EDGAR — Form 10-K FY2023 (P1574153-00) | March 2024 | Official — SEC |
| 3 | tevapharm.com — IR | Quarterly | Official — company website |
| 4 | maya.tase.co.il — Company Profile (Teva) | April 2026 | Official — Stock Exchange |
| 5 | NASDAQ.com — TEVA quote | April 2026 | Official — Stock Exchange |
| 6 | stockanalysis.com — Multiples | April 2026 | Secondary |
Missing: Pipeline R&D detail, detailed annual repayment schedule, geographic breakdown of future settlements.
